Spyre Therapeutics, Inc. Stock Deutsche Boerse AG
Stocks
3920
US00773J2024
Biotechnology & Medical Research
|
Market Closed -
Deutsche Boerse AG
02:09:06 2026-09-04 EDT
|
5-day change | 1st Jan Change | ||
| 74.00 EUR | 0.00% |
|
-6.33% | +170.07% |
| 09-04 | Spyre Therapeutics Insider Sold Shares Worth $2,480,529, According to a Recent SEC Filing | MT |
| 09-04 | Spyre Therapeutics Insider Sold Shares Worth $1,309,410, According to a Recent SEC Filing | MT |
| Market Cap | 7.85B 6.75B 6.35B 5.8B 10.85B 741B 10.88B 75.06B 29.13B 380B 29.46B 28.82B 1,224B | P/E 2026 * |
-30.4x | P/E 2027 * | -24.3x |
|---|---|---|---|---|---|
| Enterprise Value | 7.39B 6.36B 5.98B 5.47B 10.22B 698B 10.25B 70.7B 27.43B 358B 27.75B 27.15B 1,153B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
89.36% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| SYRE | Delayed | |
CBOE
| SYRE | Real-time | |
|
Tradegate
| 3920 | Real-time | |
|
Deutsche Boerse AG
| 3920 | Delayed | |
|
Börse Stuttgart
| 3920 | Delayed |
Last Transcript : Spyre Therapeutics, Inc.
| 1 week | -6.33% | ||
| Current month | -1.99% | ||
| 1 month | -18.68% | ||
| 3 months | +10.45% | ||
| 6 months | +111.43% | ||
| Current year | +170.07% |
| 1 week | 74 |  | 76.5 |
| 1 month | 74 | | 92.5 |
| Current year | 25.4 | | 92.5 |
| 1 year | 12.3 | | 92.5 |
| 3 years | 10.3 | | 92.5 |
| 5 years | 10.3 | | 92.5 |
| 10 years | 10.3 | | 92.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
Cameron Turtle
CEO | Chief Executive Officer | 36 | 2023-11-26 |
Scott Burrows
DFI | Director of Finance/CFO | 49 | 2023-08-31 |
Joshua Friedman
CTO | Chief Tech/Sci/R&D Officer | - | 2023-11-26 |
| Director | Title | Age | Since |
|---|---|---|---|
Cameron Turtle
BRD | Director/Board Member | 36 | 2023-11-26 |
Tomas Kiselak
BRD | Director/Board Member | 39 | 2023-06-21 |
| Director/Board Member | 36 | 2023-06-21 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | -6.33% | - | - | 7.85B | |
| -1.79% | -2.27% | +43.23% | +88.96% | 67.98B | |
| -2.06% | -0.18% | +39.67% | +86.44% | 64.94B | |
| -0.31% | +6.54% | -12.96% | +378.92% | 27.58B | |
| +0.86% | +1.65% | -7.74% | -14.95% | 26.06B | |
| -3.00% | -2.90% | +33.13% | +12.54% | 25.74B | |
| -1.46% | +0.42% | +23.61% | -18.61% | 20.09B | |
| -2.96% | -15.21% | +216.20% | +368.10% | 17.16B | |
| -1.49% | -4.88% | -6.60% | +531.89% | 14.92B | |
| -0.20% | +8.37% | +55.78% | +164.98% | 14.62B | |
| Average | -1.24% | +0.26% | +42.70% | +177.58% | 31.01B | |
| Weighted average by Cap. | -1.48% | +0.18% | +38.37% | +137.35% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -260M -224M -210M -192M -359M -24.53B -360M -2.49B -965M -12.59B -976M -954M -40.55B | -336M -289M -272M -249M -465M -31.74B -466M -3.22B -1.25B -16.29B -1.26B -1.23B -52.46B |
| Net Debt | -456M -392M -369M -337M -630M -43.02B -632M -4.36B -1.69B -22.07B -1.71B -1.67B -71.1B | -565M -486M -457M -418M -782M -53.35B -784M -5.41B -2.1B -27.37B -2.12B -2.08B -88.18B |
| Date | Price | Change |
|---|---|---|
| 26-09-04 | €74.00 | 0.00% |
| 26-09-03 | €74.00 | -1.99% |
| 26-09-02 | €75.50 | -0.66% |
| 26-09-01 | €76.00 | +0.66% |
| 26-08-31 | €75.50 | -4.43% |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SYRE Stock
- 3920 Stock
Select your edition
All financial news and data tailored to specific country editions
